Telomeres and Arterial Aging (TELARTA)

Short Telomere in Patients at High Cardiovascular Risk: a Simple Marker or a Major Determinant of Accelerated Arterial Aging

The prevailing view in telomere epidemiology is that leukocyte telomere length (LTL) is associated with atherosclerosis and accelerated aging since it serves as a biomarker of the cumulative burden of inflammation and oxidative stress during adult life. Our recent results however, indicate that telomere length (TL) is mainly determined at birth and childhood. Since short telomeres ante cede atherosclerosis, the investigators hypothesize that TL is not just a simple marker, but a real determinant of arterial aging. That is because TL reflects cellular repair capacity and a short LTL denotes diminished repair reserves. This hypothesis cannot be tested by measurements of LTL alone, since this parameter reflects TL at birth and its age-dependent attrition thereafter. The investigators propose, therefore, a model that makes it possible to examine different elements of TL dynamics in different tissues: leukocytes, skeletal muscle, endothelial progenitor cells (EPCs), skin or subcutaneous fat in patients with or without atherosclerosis.

Our model is based on the following premises, which are derived from observations that TL is synchronized (equivalent) across somatic tissues/cells of the newborn:

• TL in skeletal muscle mainly reflects TL at birth
• The difference in TL between muscle and leukocytes in adults (approximately 1.5 Kbp) mainly reflects LTL attrition during the growth period, i.e., childhood/adolescence
• TL in EPCs determines the cell proliferative ability and therefore capacity for vessels repair during aging.

The general aim of the present project is to examine the links of arterial aging with TL, as expressed in different tissues, and LTL dynamics, as expressed in the difference between TLs of muscle and leukocytes.

Study Overview

• Status: Unknown
• Conditions: Atherosclerotic Disease

Detailed Description

Specific objectives:

1. To determine whether TL during early development, which is primarily reflected in muscle TL, and LTL attrition during development, which is primarily expressed in the difference between muscle TL and LTL, are associated with indices of arterial aging.

2. To examine the relation between EPC-TL to endothelial regenerative capacity and endothelial function. In order to attain this objective the investigators will perform two types of experiments:

   • Measure TL in progenitor cells and relate it to clinical phenotypes of arterial aging and atherosclerosis, as well as markers of endothelial dysfunction
   • Generate in vitro progenitor cells with different TL induced by the environmental factors (oxidative stress) and assess their phenotypes concerning inflammation and microvesiculation, in order to show a possible mechanistic relationship between TL in PC and the atherogenic and the regenerative capacities of these cells.

The project is composed of 6 tasks:

T1: Recruitment and sample collection (skeletal muscle, total blood) of 170 patients with atherosclerosis and 170 controls. Performed by surgeons and cardiologists of Marseille and Nancy University hospitals T2: Characterization of arterial aging in all patients (Geriatric Dpt, Univ. hospital Nancy, Pr Benetos and AP-HM, Internal Medicine, Marseille, Dr Rossi) T3: Characterization of early and late endothelial progenitor cells (EPC): laboratory of hematology and vascular biology and in UMR_S1076 in Marseille (Prs Dignat-George and Sabatier) T4: Measurements of TL in all samples (skeletal muscle, leukocytes and EPC): UMR_S1116 Nancy (Dr Lacolley) in collaboration with Pr Aviv (University of Medicine of New Jersey) T5: Characterization of inflammation markers in blood samples: UMR_S1116 and the UMR_S1122 (Dr Siest-Visvikis, Nancy) T6: Database construction and statistical analyses (UMR_S1116)

The results of this program could completely modify the present concept on the association between TL and cardiovascular risk: Actually, if our concept of early determination of TL is valid, therefore TL could be a true determinant of the arterial aging pace, through limitation of repair capacity of cells.

• Study Type: Observational
• Enrollment (Anticipated): 340

Contacts and Locations

Study Locations

• France
  • Marseille, France, 13000
    • Not yet recruiting
    • AP Hôpitaux de Marseille
    • Contact: Pascal ROSSI, MD, PhD; Phone Number: +33.4.91.96.89.30; Email: pascalmaurice.rossi@ap-hm.fr
    • Principal Investigator: Pascal ROSSI, MD, PhD
  • Nancy, France, 54000
    • Recruiting
    • CHU Nancy
    • Contact: Athanase BENETOS, MD, PhD; Phone Number: +33.3.83.15.33.22; Email: a.benetos@chu-nancy.fr
    • Contact: Ghassan WATFA, MD, PhD; Phone Number: +33.3.83.15.33.22; Email: g.watfa@chu-nancy.fr
    • Principal Investigator: Athanase BENETOS, MD, PhD
    • Sub-Investigator: Ghassan WATFA, MD, PhD
    • Sub-Investigator: Sylvie GAUTIER, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Individuals will be recruited among patients admitted to the hospital either for surgery or for installing pacemakers/ defibrillators. Informed consent will be signed at the beginning of the hospitalization.

Description

Inclusion Criteria:

• Men and women, aged ≥ 20 years who are admitted for different types of surgery or for pacemaker/ defibrillator implantation and provide informed consent for participating in this study.

Exclusion Criteria:

Conditions which may impact telomere length:

• Patients undergoing surgery for cancer
• Patients who had had radiotherapy or chemotherapy.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
ATHEROMA group; "ATHEROMA" group will include patients undergoing cardiovascular surgery or have pacemaker/defibrillator implantation and have a clinically significant atherosclerotic disease
Control Surgery group; "Control Surgery" group will include patients undergoing other surgery or pacemaker/defibrillator implantation without evidence of clinical CV disease or history of previous CV disease.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Telomere Length (LT) dynamics	TL dynamics: as expressed in the difference between TLs of muscle and leukocytes.	up to 3 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Skin telomere length	up to 3 years
Subcutaneous fat telomere length	up to 3 years

Other Outcome Measures

Outcome Measure	Time Frame
Measure TL in progenitor cells	up to 3 years

Collaborators and Investigators

• Sponsor: Central Hospital, Nancy, France
• Collaborators: Assistance Publique Hopitaux De Marseille; Institut National de la Santé Et de la Recherche Médicale, France; National Research Agency, France; University of Lorraine
• Investigators: Principal Investigator: Athanase BENETOS, MD, PhD, Service de Gériatrie et INSERM U1116; Université de Lorraine et CHU de Nancy; France

Publications and helpful links

General Publications

• Toupance S, Simonici S, Labat C, Dumoulin C, Lai TP, Lakomy C, Regnault V, Lacolley P, Dignat George F, Sabatier F, Aviv A, Benetos A; TELARTA consortium dagger. Number and Replating Capacity of Endothelial Colony-Forming Cells are Telomere Length Dependent: Implication for Human Atherogenesis. J Am Heart Assoc. 2021 May 18;10(10):e020606. doi: 10.1161/JAHA.120.020606. Epub 2021 May 6.
• Benetos A, Toupance S, Gautier S, Labat C, Kimura M, Rossi PM, Settembre N, Hubert J, Frimat L, Bertrand B, Boufi M, Flecher X, Sadoul N, Eschwege P, Kessler M, Tzanetakou IP, Doulamis IP, Konstantopoulos P, Tzani A, Korou M, Gkogkos A, Perreas K, Menenakos E, Samanidis G, Vasiloglou-Gkanis M, Kark JD, Malikov S, Verhulst S, Aviv A. Short Leukocyte Telomere Length Precedes Clinical Expression of Atherosclerosis: The Blood-and-Muscle Model. Circ Res. 2018 Feb 16;122(4):616-623. doi: 10.1161/CIRCRESAHA.117.311751. Epub 2017 Dec 14.

Study record dates

Study Major Dates

• Study Start: June 1, 2014
• Primary Completion (Anticipated): November 1, 2016
• Study Completion (Anticipated): November 1, 2016

Study Registration Dates

• First Submitted: June 26, 2014
• First Submitted That Met QC Criteria: June 26, 2014
• First Posted (Estimate): June 27, 2014

Study Record Updates

• Last Update Posted (Estimate): June 16, 2016
• Last Update Submitted That Met QC Criteria: June 15, 2016
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Keywords: Inflammation; Atherosclerosis; Endothelial Progenitor Cells; Telomere Length; Arterial Aging
• Other Study ID Numbers: 2014-A00298-39